Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005–2018)

Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005–2018)

Background: Rituximab combined with cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R–CHOP) regimen has improved the survival of diffuse large B-cell lymphoma (DLBCL) patients worldwide, compared with CHOP alone. Several limitations were seen in previous studies of Chinese...

Full description

Bibliographic Details
Main Authors: Yuankai Shi, Haizhu Chen, Yan Qin, Jianliang Yang, Peng Liu, Xiaohui He, Shengyu Zhou, Liqiang Zhou, Changgong Zhang, Yongwen Song, Yueping Liu, Lin Gui, Shulian Wang, Jing Jin, Hui Fang, Shunan Qi, Ning Li, Yu Tang, Xin Wang, Sheng Yang
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:Cancer Pathogenesis and Therapy
Subjects:
Diffuse large B-Cell lymphoma
Treatment
Prognosis
SEER database
Online Access:http://www.sciencedirect.com/science/article/pii/S2949713222000064

Internet

http://www.sciencedirect.com/science/article/pii/S2949713222000064

Similar Items